Abstract
The clinical success of cisplatin continues to inspire the development of metal-based anticancer drug candidates. This article is meant to present the current state-of-the-art and science of ruthenium(II)- and rhenium(I)-based anticancer drug candidates born out of our work in this field. Our recent efforts to elicit photoactivation of intact (organo)metallic anticancer drug candidates as a promising way for commanding their activity within cancer cells are also briefly summarized. 1 Introduction 2 Ruthenium(II) Complexes 3 Rhenium(I) Complexes 4 Concluding Remarks
| Original language | English |
|---|---|
| Pages (from-to) | 275-284 |
| Number of pages | 10 |
| Journal | Synlett |
| Volume | 26 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2015 |
Keywords
- antitumor agents,
- carbonyl complexes
- drugs
- medicinal chemistry
- ruthenium
- photochemistry
